Table of Contents

1 Study Coverage

• 1.1 Generic Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Generic Drugs Market Size Growth Rate by Product
  • 1.4.2 Simple Generic Drugs
  • 1.4.3 Super Generic Drugs
  • 1.4.4 Biosimilars
• 1.5 Market by End User
  • 1.5.1 Global Generic Drugs Market Size Growth Rate by End User
  • 1.5.2 CNS
  • 1.5.3 Cardiovascular
  • 1.5.4 Genitourinary/Hormonal Drugs
  • 1.5.5 Respiratory
  • 1.5.6 Rheumatology
  • 1.5.7 Diabetes
  • 1.5.8 Oncology
  • 1.5.9 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Generic Drugs Market Size
  • 2.1.1 Global Generic Drugs Revenue 2014-2025
  • 2.1.2 Global Generic Drugs Sales 2014-2025
• 2.2 Generic Drugs Growth Rate by Regions
  • 2.2.1 Global Generic Drugs Sales by Regions
  • 2.2.2 Global Generic Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Generic Drugs Sales by Manufacturers
  • 3.1.1 Generic Drugs Sales by Manufacturers
  • 3.1.2 Generic Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Generic Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Generic Drugs Revenue by Manufacturers
  • 3.2.1 Generic Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Generic Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Generic Drugs Price by Manufacturers
• 3.4 Generic Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Generic Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Generic Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Generic Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Generic Drugs Sales by Product
• 4.2 Global Generic Drugs Revenue by Product
• 4.3 Generic Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Generic Drugs Breakdown Data by End User

6 North America

• 6.1 North America Generic Drugs by Countries
  • 6.1.1 North America Generic Drugs Sales by Countries
  • 6.1.2 North America Generic Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Generic Drugs by Product
• 6.3 North America Generic Drugs by End User

7 Europe

• 7.1 Europe Generic Drugs by Countries
  • 7.1.1 Europe Generic Drugs Sales by Countries
  • 7.1.2 Europe Generic Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Generic Drugs by Product
• 7.3 Europe Generic Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Generic Drugs by Countries
  • 8.1.1 Asia Pacific Generic Drugs Sales by Countries
  • 8.1.2 Asia Pacific Generic Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Generic Drugs by Product
• 8.3 Asia Pacific Generic Drugs by End User

9 Central & South America

• 9.1 Central & South America Generic Drugs by Countries
  • 9.1.1 Central & South America Generic Drugs Sales by Countries
  • 9.1.2 Central & South America Generic Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Generic Drugs by Product
• 9.3 Central & South America Generic Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Generic Drugs by Countries
  • 10.1.1 Middle East and Africa Generic Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Generic Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Generic Drugs by Product
• 10.3 Middle East and Africa Generic Drugs by End User

11 Company Profiles

• 11.1 Teva
  • 11.1.1 Teva Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Teva Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Teva Generic Drugs Products Offered
  • 11.1.5 Teva Recent Development
• 11.2 Novartis - Sandoz
  • 11.2.1 Novartis - Sandoz Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novartis - Sandoz Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novartis - Sandoz Generic Drugs Products Offered
  • 11.2.5 Novartis - Sandoz Recent Development
• 11.3 Mylan
  • 11.3.1 Mylan Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Mylan Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Mylan Generic Drugs Products Offered
  • 11.3.5 Mylan Recent Development
• 11.4 Sun Pharmaceutical
  • 11.4.1 Sun Pharmaceutical Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Sun Pharmaceutical Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Sun Pharmaceutical Generic Drugs Products Offered
  • 11.4.5 Sun Pharmaceutical Recent Development
• 11.5 Aspen
  • 11.5.1 Aspen Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Aspen Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Aspen Generic Drugs Products Offered
  • 11.5.5 Aspen Recent Development
• 11.6 Fresenius Kabi
  • 11.6.1 Fresenius Kabi Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Fresenius Kabi Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Fresenius Kabi Generic Drugs Products Offered
  • 11.6.5 Fresenius Kabi Recent Development
• 11.7 Pfizer (Hospira)
  • 11.7.1 Pfizer (Hospira) Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Pfizer (Hospira) Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Pfizer (Hospira) Generic Drugs Products Offered
  • 11.7.5 Pfizer (Hospira) Recent Development
• 11.8 Sanofi
  • 11.8.1 Sanofi Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Sanofi Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Sanofi Generic Drugs Products Offered
  • 11.8.5 Sanofi Recent Development
• 11.9 Aurobindo
  • 11.9.1 Aurobindo Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Aurobindo Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Aurobindo Generic Drugs Products Offered
  • 11.9.5 Aurobindo Recent Development
• 11.10 Lupin
  • 11.10.1 Lupin Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Lupin Generic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Lupin Generic Drugs Products Offered
  • 11.10.5 Lupin Recent Development
• 11.11 Dr. Reddy's
• 11.12 Apotex
• 11.13 Cipla
• 11.14 ENDO (Par Pharmaceutical)
• 11.15 Stada Arzneimittel
• 11.16 Krka Group
• 11.17 Nichi-Iko Pharmaceutical
• 11.18 Valeant
• 11.19 Zydus Cadila
• 11.20 Hikma

12 Future Forecast

• 12.1 Generic Drugs Market Forecast by Regions
  • 12.1.1 Global Generic Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Generic Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Generic Drugs Market Forecast by Product
  • 12.2.1 Global Generic Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Generic Drugs Revenue Forecast by Product 2019-2025
• 12.3 Generic Drugs Market Forecast by End User
• 12.4 North America Generic Drugs Forecast
• 12.5 Europe Generic Drugs Forecast
• 12.6 Asia Pacific Generic Drugs Forecast
• 12.7 Central & South America Generic Drugs Forecast
• 12.8 Middle East and Africa Generic Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Generic Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
The global average gross margin of generic drugs is in the decreasing trend, from 45.19% in 2011 to 43.56% in 2015. With the situation of global economy, gross margin will be in decreasing trend in the following five years.
The classification of generic drugs includes simple generic drugs, super generic drugs and biosimilars. And the proportion of simple generic drugs in 2015 is about 80% and the proportion is in decreasing trend from 2011 to 2015. The super generic drugs in 2015 are about 18.7% and the proportion is in increasing trend from 2011 to 2015.
North America region is the largest supplier of generic drugs, with a revenue market share nearly 31.5% in 2015. Europe is the second largest supplier of generic drugs, enjoying revenue market share nearly 26.5% in 2015, India is also an important areas, and with the revenue market share is 22.8% in 2015.
The global Generic Drugs market is valued at 210800 million US$ in 2018 and will reach 451800 million US$ by the end of 2025, growing at a CAGR of 10.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Generic Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Generic Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Generic Drugs in these regions.
This research report categorizes the global Generic Drugs market by top players/brands, region, type and end user. This report also studies the global Generic Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma

Market size by Product
Simple Generic Drugs
Super Generic Drugs
Biosimilars
Market size by End User
CNS
Cardiovascular
Genitourinary/Hormonal Drugs
Respiratory
Rheumatology
Diabetes
Oncology
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Generic Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Generic Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Generic Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Generic Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Generic Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Generic Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.